Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The REALITY of it is that Aducanumab will not be approved simply because its MoA has been proven to be a failure. When the results of AVXL continue to be positive, any interest in Aducanumab will greatly diminish.
http://www.fiercebiotech.com/biotech/biogen-s-aducanumab-data-impresses-media-but-not-market?utm_medium=nl&utm_source=internal&mrkid=34572939&mkt_tok=eyJpIjoiWm1SaVpEZG1PRFl4WWprMiIsInQiOiJWVFNqYjAzcmdDUStHTXFSVEdNUFo0RnNITWtWUjU3VmVLM2NDRVJ2VW9KcGpTWWI5VHB1YVh3cG8wVXVzeXVERzFPbkY0VU1JWmViemNvXC9qTXBCZzNxc002OGdTXC9NR2lTYXZLK0FlM2lrPSJ9
I'm hoping that one day the U.S. will adopt the position of Germany and outlaw short selling. It serves no purpose than to allow criminals to steal from honest investors.
One should only be allowed to sell the shares they actually own.
But we all know, that too many SEC officials and congressmen are likely paid off to never let short selling be outlawed.
Actually, there are over 500k shares available for shorting, more than previous, which indicates shorts are beginning to cover as they can. Hard to do when no one is selling.
For which purpose... to try to bring in buyers to move the price up or to attract more shares to short?
Seems if they truly wanted to accumulate in a controlled manner, they would use a number of smaller bids.
That's certainly a possibility. Actually, that thought crossed my mind leading up to AAIC, after the CTAD experience. Though, it really depends upon the data. I'm expecting we'll see good 38-wk and other positive news, between now and then, that will give us better confidence for CTAD.
My math puts 52-wk in Dec, if 38-wk is in Sept. Also, CTAD is early Dec this year.
Thanks, but I don't want to invest in companies who gouge their customers (i.e. the patients who are in need of their drugs). I would have preferred to short it on the announcement.
Isn't it illegal to not deliver the shares? If so, why isn't it being addressed? Is the SEC not doing its job or perhaps on the take?
Nice post, Wave. Those who deny are either naive or part of the scam.
Of course, there is the VERY RARE situation where the purchase settlement is not made within 3 days, because of some unusual processing delays (noted below), but those are a rarity. By and large, 99% of all "fails to deliver" are related to naked short selling.
"There may be legitimate reasons for a failure to deliver. For example, human or mechanical errors or processing delays can result from transferring securities in physical certificate rather than book-entry form, thus causing a failure to deliver on a long sale within the normal three-day settlement period."
You ask funny questions.
Nice summary of the past PRs and articles...
From your link, I could not find any instances where "fails to deliver" applies to a net long position...only shorting. So, "wrong" applies until you prove otherwise...
Current regulatory requirements applicable to short sales of equity securities are generally found in Regulation SHO, which the Commission adopted to address its concerns regarding persistent fails to deliver and potentially abusive “naked” short selling. A “naked” short sale generally refers to selling short without having borrowed the securities to make delivery. All sellers of securities should promptly deliver, or arrange for delivery of, securities and all buyers of securities have a right to expect prompt delivery of securities purchased. The Commission was concerned about the negative effect that fails to deliver may have on the markets and shareholders. For example, large and persistent fails to deliver may deprive shareholders of the benefits of ownership, such as voting and lending, and sellers that fail to deliver securities on settlement date may attempt to use this additional freedom to engage in trading activities to improperly depress the price of a security.
Wrong. Fail to deliver only applies to naked shorting.
It's not LPC who's shorting; they are forbidden by the mutual agreement. We all know who's behind the coordinated short attacks, and it's not LPC.
Being in an oversold area, with any number of potential PRs coming, would suggest there is more risk to the down side than up. Anyone selling here, at a loss, in hopes of buying lower will likely end up chasing it higher.
I didn't say anything about the time. But it would still be quicker than starting over with a reformulated 2-73.
Would you mind going through and correcting it for us?
Marino, keep buying! We need momentum! :)
I don't expect any serious buying until after Labor Day, unless there is a catalyst. I wouldn't want to be out of the stock when Sept 6th rolls around...just in case.
The below link is to a report on all of the current Alz trials listed on clinicaltrials.gov, as of Jan 4, 2016, identifying all 93 agents, their MoAs and their various trials and stages (Phase I, II, III).
It's worth noting that 2-73 is the ONLY agent identified with an MoA of "Sigma-1 Receptor Agonist".
http://www.trci.alzdem.com/article/S2352-8737(16)30019-1/pdf
One just needs to review the last corporate presentation and look at the drugs already in their pipeline.
They would advance 3-71 before they would "adjust" 2-73, as that would put them back at the starting line.
They already have the next drug in the pipeline...3-71!
Try contacting A Current Affair in Sydney...
Below link is to an interesting study about a gene mutation believed to be involved in various CNS disorders. Supposedly, this gene mutation is involved in protein degradation and the process of neurodegeneration.
Perhaps 2-73 prevents the gene mutation, which in turn prevents protein degradation (that leads to misfolding causing beta-amyloid plaque and tau tangles?). Just maybe...
https://alzheimersnewstoday.com/2016/08/22/park-hunt-researchers-identify-single-gene-protect-neurodegenerative-diseases/?utm_source=Alzheimer%27s+List&utm_campaign=e97ed44997-RSS_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_94425accb7-e97ed44997-71697525
Are you suggesting that the 190k share bid yesterday at 3.13 is not smart money buying in? I think it is and there will be much more in the coming weeks.
Before CTAD, I'm expecting PRs on one or more of the following:
PK/PD data, 38-wk update, Rett's P2 announcement, Parkinson's update and potentially a partner and/or grant announcement.
Many catalysts on the horizon; time is our friend: PK/PD data; Rett's P2 trial; Parkinson's P2 trial; Alz P2b/3 trial; Partnership and/or Grants; BTD, Fast Track... all in due time!
Which one will we hear about first? Anyone?
Excerpt from AXON's Aug 15 PR... it touts its combo technology with donepezil to advance the SoC by reducing the adverse side effects of donepezil. This is no solution for Alz; it's just trying to make donepezil less bad. (i.e. lipstick on pig)
"Axovant and Qaam Pharmaceuticals (Qaam) have entered into an exclusive license agreement under which Axovant expects to develop and, if successful, commercialize products that combine cholinesterase inhibitors with peripheral muscarinic receptor antagonists including glycopyrrolate, which could mitigate the peripheral side effects of cholinesterase inhibitors. Axovant will initially develop RVT-103, a combination of glycopyrrolate and donepezil. In addition, Axovant expects to develop RVT-104, a combination of glycopyrrolate and high-dose rivastigmine. Axovant believes that the intellectual property portfolio licensed from Qaam as part of this transaction provides a strong exclusivity position in this area."
"This program continues to build on our efforts to deliver comprehensive solutions to patients diagnosed with dementia," said Axovant Chief Development Officer Dr. Lawrence Friedhoff, who led the development of Aricept (donepezil) for the treatment of Alzheimer's disease through its approval in 1996. "We believe this product candidate can limit the peripheral side effects of cholinesterase inhibitors which frequently represent an obstacle for patients to adopt or remain on therapy."
Someone should author a hit piece on AXON revealing the truth about its flawed approach on an ineffective SOC, and post it on MF and SA. Seriously! Would like to see the responses from AF, JF, CR and the rest of the cabal who support this lame company.
It will not take that long to get patients for a small trial for a disease that affects children. Parents will be eager and willing, knowing the drug is safe. They might have already started to identify potential patients.
Approval for Rett's may very well be the fastest way 2-73 gets approved. If the trial starts in Sept, approval could realistically come in Q1 2017.
PK stands for pharmacokinetic analysis. It's an analysis of how the body processes the drug: distribution, metabolism and excretion. PD (pharmacodynamics) is the corresponding analysis of how the drug affects the body, dosage response and biometrically how well it is hitting its target, etc.
That's like saying, why buy insurance if you're not planning to use it?.
I do not believe there was any proof of AVXL paying for any "pump" promotions. The Argos pump piece was certainly not of AVXL's doing. I firmly believe it was paid by the cabal who were behind pumping up the price in preparation of their planned short attack.
Yes, you're correct; "attack" is the wrong word; should have used "target" instead. Thanks!
Correct... Attacking beta-amyloid, instead of the cause, is analogous to a leaky boat. Bailing out the water will not fix the problem! No matter how advanced your bucket or techniques are.
I doubt they'll use the LPC funds, but if they do, I would suspect they would either be buying time to negotiate more favorable partnership terms...or possibly decide to go it alone (utilizing a drug mfr/distributor instead).
IF they do tap into the LPC funds, I would imagine they would time the transaction after some very good news in order to execute at a more optimal stock price.
I would suspect that those patients were not MCI, but rather mild-to-moderate Alz patients for the simple fact that they had given up their hobbies for a period of time (perhaps years). I doubt an MCI patient would be so afflicted to give up on a hobbie. IMO, of course.
I don't believe you fully understand the purpose of an adaptive open-label trial, which was approved by the FDA. It met its endpoints and the data will enable the company to design a meaningful Phase 3 with a high probability of success.
There is more to this drug (MoA) than just Alzheimer's. Great things are about to happen, including a partner and/or grant.
Yep, and notice that the 5-day money-flow indicator has risen through all of this manipulation...a very unnatural correlation. Appears the conniving crooks are positioning themselves (and their cronies) for the next leg up on the next bit of news.
What do you believe the next catalyst will be and approx. when?